Position in ANAB
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,021,849
-$705,789 QoQ
Shares Held
27,638
-67.3% QoQ
Ownership
0.095%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
126,005 | $33,608,053 | |
| 2 | CYTK |
Cytokinetics Inc
|
239,728 | $20,422,428 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
288,233 | $16,492,692 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
386,183 | $14,393,040 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,596 | $14,089,509 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
334,854 | $11,180,775 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
347,898 | $11,111,862 | |
| 8 | BCAX |
Bicara Therapeutics Inc.
|
353,226 | $10,487,279 |
All Filings in ANAB
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,021,849 | 18,425 | Shares | Sole | 2026-05-13 | |
| 2025-09-30 | $1,727,638 | 56,422 | Shares | Sole | 2025-11-14 | |
| 2024-09-30 | $5,493,891 | 163,997 | Shares | Sole | 2024-11-14 | |
| 2024-03-31 | $203,017 | 9,015 | Shares | Sole | 2024-05-15 | |
| 2023-03-31 | $222,714 | 10,235 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $352,635 | 11,379 | Shares | Sole | 2023-02-14 | |
| 2021-12-31 | $2,702,997 | 77,784 | Shares | Sole | 2022-05-27 | |
| 2020-09-30 | $308,775 | 20,934 | Shares | Sole | 2020-11-16 | |
| 2020-03-31 | $150,456 | 10,648 | Shares | Sole | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||